UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

Archives

2025
- March
- February
- January
2024
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January

Mar

07 Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Read More Share:

|

Mar

07 BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Read More Share:

|

Mar

07 BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Read More Share:

|

Mar

05 Voices on Value: Prioritizing Patients Now and Into the Future

Read More Share:

|

Mar

04 CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Read More Share:

|

Categories

Archives

Mar

07

Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Mar

05

Voices on Value: Prioritizing Patients Now and Into the Future

Mar

04

CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Mar

07

Improving Dermatology Outcomes with Timely Diagnosis and Long-Lasting Treatment Options

Mar

07

BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden

Mar

07

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis

Mar

05

Voices on Value: Prioritizing Patients Now and Into the Future

Mar

04

CareCompass: Transforming the care journey of caregivers and their loved ones with Dravet Syndrome or Lennox-Gastaut Syndrome

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact